Literature DB >> 15218514

Analysis of the EFEMP1 gene in individuals and families with early onset drusen.

N Narendran1, R H Guymer, M Cain, P N Baird.   

Abstract

AIMS: Age-related macular degeneration (AMD) is considered a complex genetic disease, although the genetic influences are not yet fully understood. Genetic analysis is hampered by the late onset of disease and the difficulty in obtaining multigenerational families. To investigate this problem further we studied our population of early onset drusen cases. The Arg345Trp mutation on exon 10 of the EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1) gene causes two clinical phenotypes of early onset drusen (Doyne honeycomb retinal dystrophy and Malattia Leventinese), yet does not appear to be involved in other early onset drusen phenotypes or typical AMD. We wished to ascertain the involvement of the EFEMP1 gene in our population of sporadic and familial subjects presenting with early onset drusen and their affected relatives.
METHODS: Individuals presenting with drusen/end-stage maculopathy at 60 years or under were identified from retinal clinics in Melbourne. All available first- and second-degree relatives were also examined. In all, 116 ethnically matched controls were collected from the same community for comparison.
RESULTS: Single stranded conformational polymorphism (SSCP) analysis and subsequent sequencing revealed four previously described and three novel sequence variations. Most occurred at similar frequencies in the case and control populations and were not thought to be disease associated.
CONCLUSION: The term early onset drusen encompasses a wide range of phenotypes and our findings indicate that it is likely that more than one gene is involved in its causation. It is essential that these clinical phenotypes are well described and categorised to allow greater possibility of success in the search for other disease genes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15218514     DOI: 10.1038/sj.eye.6701435

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  7 in total

Review 1.  Genetics of age-related macular degeneration: current concepts, future directions.

Authors:  Margaret M Deangelis; Alexandra C Silveira; Elizabeth A Carr; Ivana K Kim
Journal:  Semin Ophthalmol       Date:  2011-05       Impact factor: 1.975

Review 2.  Genetics of immunological and inflammatory components in age-related macular degeneration.

Authors:  Jingsheng Tuo; Seanna Grob; Kang Zhang; Chi-Chao Chan
Journal:  Ocul Immunol Inflamm       Date:  2012-02       Impact factor: 3.070

3.  A novel haplotype with the R345W mutation in the EFEMP1 gene associated with autosomal dominant drusen in a Japanese family.

Authors:  Tomokazu Takeuchi; Takaaki Hayashi; Matthew Bedell; Kang Zhang; Hisashi Yamada; Hiroshi Tsuneoka
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-22       Impact factor: 4.799

4.  Analysis of variants in Chinese individuals with primary open-angle glaucoma using molecular inversion probe (MIP)-based panel sequencing.

Authors:  Ting Liu; Chao Tang; Xiaolong Shi
Journal:  Mol Vis       Date:  2020-05-21       Impact factor: 2.367

5.  Diagnostic definition of malattia leventinese in a family from Colombia

Authors:  Nancy Gelvez; Paula Hurtado-Villa; Silvia Flórez; Anne Charlotte Brieke; Francisco Rodríguez; Ana María Bertolotto; Martha L Tamayo
Journal:  Biomedica       Date:  2021-09-22       Impact factor: 0.935

6.  First reported case of Doyne honeycomb retinal dystrophy (Malattia Leventinese/autosomal dominant drusen) in Scandinavia.

Authors:  Inger Norlyk Sheyanth; Ihab Bishara Lolas; Henrik Okkels; Ligor Pradeep Kiruparajan; Søren Kromann Abildgaard; Michael Bjørn Petersen
Journal:  Mol Genet Genomic Med       Date:  2021-03-10       Impact factor: 2.183

7.  Decrease of fibulin-3 in hepatocellular carcinoma indicates poor prognosis.

Authors:  Rongzhen Luo; Meifang Zhang; Lili Liu; Shixun Lu; Chris Zhiyi Zhang; Jingping Yun
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.